Showing results (101-110 of 152) with videos related to
Sort By:
Pageof 16
European Journal of Nuclear Medicine and Molecular Imaging|April 3, 2015
(11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areasEunkyung Park, Jean-Dominique Gallezot, Aracely Delgadillo, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MSJens Kuhle, Nadia Daizadeh, Pascal Benkert, et al.Ebiomedicine|June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsAmit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.Journal of Neuroinflammation|May 2, 2021
Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorderPatrick Schindler, Ulrike Grittner, Johanna Oechtering, et al.Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2023
Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosisDavid Leppert, Mitsuru Watanabe, Sabine Schaedelin, et al.Neurology|July 18, 2020
Serum neurofilament light as a biomarker in progressive multiple sclerosisRaju Kapoor, Kathryn E Smith, Mark Allegretta, et al.Neurology(R) Neuroimmunology & Neuroinflammation|April 11, 2020
Monitoring of radiologic disease activity by serum neurofilaments in MSTomas Uher, Sabine Schaedelin, Barbora Srpova, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 17, 2022
Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MSHrishikesh Lokhande, Mattia Rosso, Shahamat Tauhid, et al.European Journal of Neurology|February 2, 2026
Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple SclerosisNahid Moradi, Sifat Sharmin, Charles B Malpas, et al.JAMA Neurology|August 13, 2019
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 YearsEster Cantó, Christian Barro, Chao Zhao, et al.Pageof 16